Global Hemophilia Market Size, Share & Trends Analysis Report By Type (Hemophilia A, Hemophilia B, and, Others), By Therapy (Replacement Therapy, Gene Therapy, and Others), By Product Type (Recombinant Coagulation Factor Concentrates, Plasma-derived Coagulation Factor Concentrates and Others) Forecast Period (2020-2026).
The global hemophilia market is anticipated to grow at a CAGR of 6% during the forecast period. Hemophilia is a disease associated with the genetic inheritance in which patients are not able to produce sufficient amounts of the blood clotting proteins. Hence, in cases of injury, the clotting of blood is very slow in patients as a result patients often suffer spontaneous, painful bleeding into muscle tissue and joints. The increasing awareness regarding the condition and increasing disposable income of people across the globe is driving the hemophilia market growth.
The global hemophilia market is segmented based on type, therapy, and product type. Based on the type, the market is sub-segmented into hemophilia A, hemophilia B, and others. Based on the therapy, the market is sub-segmented into replacement therapy, gene therapy, and others. Further, based on the product type, the market is subdivided into recombinant coagulation factor concentrates, plasma-derived coagulation, and other factor concentrates.
The global hemophilia market is further segmented based on geography including North America, Europe, Asia-Pacific, and the Rest of the World. North America is expected to show significant growth with a considerable market share during the forecast period. The growth in the region is owing to the high diagnosis rate and the ability to spend a high amount on the treatment.
The key players of the global hemophilia market include Baxter International, Inc., BioMarin Pharmaceutical Inc., CSL Ltd., F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including merger & acquisition, collaborations with government, funding, new drug launches, and various other advancements to stay competitive in the market. For instance, in April 2019, Novo Nordisk A/S invested approximately100 million in its production site in Kalundborg, Denmark, for the upgrading and expansion of the facilities to ramp up its hemophilia drug production.
Research Methodology:
The market study of the global hemophilia market is incorporated by extensive primary and secondary research. Secondary research has been conducted to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.
Secondary Sources Include:
The report is intended for the drug manufacturers, hospitals & clinics, insurance companies, government, and other related industries for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, products offered by the companies, and future market opportunities. The report will serve as a source for a 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.
Market Segmentation:
1. Global Hemophilia Market Research and Analysis by Type
2. Global Hemophilia Market Research and Analysis by Therapy
3. Global Hemophilia Market Research and Analysis by Product Type
The Report Covers:
The global hemophilia market is anticipated to grow at a CAGR of 6% during the forecast period. Hemophilia is a disease associated with the genetic inheritance in which patients are not able to produce sufficient amounts of the blood clotting proteins. Hence, in cases of injury, the clotting of blood is very slow in patients as a result patients often suffer spontaneous, painful bleeding into muscle tissue and joints. The increasing awareness regarding the condition and increasing disposable income of people across the globe is driving the hemophilia market growth.
The global hemophilia market is segmented based on type, therapy, and product type. Based on the type, the market is sub-segmented into hemophilia A, hemophilia B, and others. Based on the therapy, the market is sub-segmented into replacement therapy, gene therapy, and others. Further, based on the product type, the market is subdivided into recombinant coagulation factor concentrates, plasma-derived coagulation, and other factor concentrates.
The global hemophilia market is further segmented based on geography including North America, Europe, Asia-Pacific, and the Rest of the World. North America is expected to show significant growth with a considerable market share during the forecast period. The growth in the region is owing to the high diagnosis rate and the ability to spend a high amount on the treatment.
The key players of the global hemophilia market include Baxter International, Inc., BioMarin Pharmaceutical Inc., CSL Ltd., F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including merger & acquisition, collaborations with government, funding, new drug launches, and various other advancements to stay competitive in the market. For instance, in April 2019, Novo Nordisk A/S invested approximately100 million in its production site in Kalundborg, Denmark, for the upgrading and expansion of the facilities to ramp up its hemophilia drug production.
Research Methodology:
The market study of the global hemophilia market is incorporated by extensive primary and secondary research. Secondary research has been conducted to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.
Secondary Sources Include:
- Financial reports of companies involved in the market.
- Whitepapers, research-papers, and news blogs.
- Company websites and their product catalog.
The report is intended for the drug manufacturers, hospitals & clinics, insurance companies, government, and other related industries for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, products offered by the companies, and future market opportunities. The report will serve as a source for a 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.
Market Segmentation:
1. Global Hemophilia Market Research and Analysis by Type
2. Global Hemophilia Market Research and Analysis by Therapy
3. Global Hemophilia Market Research and Analysis by Product Type
The Report Covers:
- Comprehensive research methodology of the global hemophilia market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the global hemophilia market.
- Insights about market determinants which are stimulating the global hemophilia market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
Table of Contents
1. Report Summary
2. Market Overview and Insights
3. Competitive Landscape
4. Market Determinants
5. Market Segmentation
6. Regional Analysis
7. Company Profiles
Companies Mentioned
A selection of companies mentioned in this report includes:
- Alnylam Pharmaceuticals, Inc
- Baxter International, Inc.
- Bayer AG
- BioMarin Pharmaceutical Inc.
- Biotest AG
- Catalyst Biosciences Inc.
- CSLLtd.
- Emergent BioSolutions Inc.
- F. Hoffmann-La Roche Ltd.
- GC Pharma (Green Cross Corp.)
- Genentech Inc. (HEMLIBRA)
- Grifols, S.A.
- Kedrion S.p.A
- Medexus Pharmaceuticals, Inc.
- Nektar Therapeutics
- Novo Nordisk A/S
- Octapharma AG
- Pfizer, Inc.
- Sanofi SA
- Spark Therapeutics, Inc.
- Swedish Orphan Biovitrum AB
- Takeda Pharmaceutical Company Ltd.
